On April 4, 2019, we entered into license agreements with Medigene to develop, manufacture, and commercialize Medigene's research-stage TCR-T therapy targeting the NY-ESO-1 cancer-testis antigen and a DC vaccine presenting the WT1 and PRAME oncoprotein antigens, in Greater China, Japan, and South Korea. Additionally, we entered into a strategic collaboration and discovery agreement for TCR-T therapies for two additional targets which we intend to develop and commercialize in the same territory.